580 related articles for article (PubMed ID: 32707982)
21. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
22. Engineering Natural Killer Cells for Cancer Immunotherapy.
Rezvani K; Rouce R; Liu E; Shpall E
Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
[TBL] [Abstract][Full Text] [Related]
23. [Development of allogeneic CAR T-cells].
Alcazer V; Depil S
Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy.
Lin C; Zhang J
Sci China Life Sci; 2019 May; 62(5):633-639. PubMed ID: 30796720
[TBL] [Abstract][Full Text] [Related]
25. CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy.
Rotolo R; Leuci V; Donini C; Cykowska A; Gammaitoni L; Medico G; Valabrega G; Aglietta M; Sangiolo D
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31212634
[TBL] [Abstract][Full Text] [Related]
26. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.
Elahi R; Heidary AH; Hadiloo K; Esmaeilzadeh A
Stem Cell Rev Rep; 2021 Dec; 17(6):2081-2106. PubMed ID: 34472037
[TBL] [Abstract][Full Text] [Related]
27. CAR T cells: Building on the CD19 paradigm.
Globerson Levin A; Rivière I; Eshhar Z; Sadelain M
Eur J Immunol; 2021 Sep; 51(9):2151-2163. PubMed ID: 34196410
[TBL] [Abstract][Full Text] [Related]
28. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
29. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
[TBL] [Abstract][Full Text] [Related]
30. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
Locatelli F; Merli P; Rutella S
J Leukoc Biol; 2013 Dec; 94(6):1141-57. PubMed ID: 24096380
[TBL] [Abstract][Full Text] [Related]
31. Target tumor microenvironment by innate T cells.
Li YR; Wilson M; Yang L
Front Immunol; 2022; 13():999549. PubMed ID: 36275727
[TBL] [Abstract][Full Text] [Related]
32. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
33. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
34. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
Zhao Y; Zhou X
Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
[TBL] [Abstract][Full Text] [Related]
35. A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases.
Hassan SH; Alshahrani MY; Saleh RO; Mohammed BA; Kumar A; Almalki SG; Alkhafaji AT; Ghildiyal P; Al-Tameemi AR; Elawady A
Med Oncol; 2024 Apr; 41(6):127. PubMed ID: 38656354
[TBL] [Abstract][Full Text] [Related]
36. Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy.
Cortés-Selva D; Dasgupta B; Singh S; Grewal IS
Trends Pharmacol Sci; 2021 Jan; 42(1):45-59. PubMed ID: 33250273
[TBL] [Abstract][Full Text] [Related]
37. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.
Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ
Front Immunol; 2024; 15():1384039. PubMed ID: 38726000
[TBL] [Abstract][Full Text] [Related]
38. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
Lamers-Kok N; Panella D; Georgoudaki AM; Liu H; Özkazanc D; Kučerová L; Duru AD; Spanholtz J; Raimo M
J Hematol Oncol; 2022 Nov; 15(1):164. PubMed ID: 36348457
[TBL] [Abstract][Full Text] [Related]
39. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
40. Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology.
Schmidt P; Raftery MJ; Pecher G
Front Immunol; 2020; 11():611163. PubMed ID: 33488617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
